丸美生物：拟在港交所主板上市发行H股

Core Viewpoint - The company has approved a proposal for an initial public offering (IPO) of overseas-listed shares on the Hong Kong Stock Exchange to enhance its capital strength and overseas financing capabilities, accelerating its internationalization strategy [1] Group 1: IPO Details - The company plans to issue H-shares with a par value of RMB 1, available for subscription in foreign currency [1] - The total issuance scale will not exceed 15% of the total share capital post-issuance, with an option for underwriters to exercise an over-allotment option of up to 15% of the shares [1] - All proposals are subject to approval by the shareholders' meeting [1]